Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Other Non-Current Liabilities (2023 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Other Non-Current Liabilities for 4 consecutive years, with $338000.0 as the latest value for Q2 2025.

  • On a quarterly basis, Other Non-Current Liabilities fell 97.39% to $338000.0 in Q2 2025 year-over-year; TTM through Apr 2025 was $338000.0, a 97.39% decrease, with the full-year FY2025 number at $338000.0, down 97.39% from a year prior.
  • Other Non-Current Liabilities was $338000.0 for Q2 2025 at PharmaCyte Biotech, down from $6.9 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $15.6 million in Q4 2023 to a low of $338000.0 in Q2 2025.
  • A 3-year average of $7.4 million and a median of $6.9 million in 2024 define the central range for Other Non-Current Liabilities.
  • Peak YoY movement for Other Non-Current Liabilities: crashed 55.88% in 2024, then tumbled 97.39% in 2025.
  • PharmaCyte Biotech's Other Non-Current Liabilities stood at $15.6 million in 2023, then crashed by 55.88% to $6.9 million in 2024, then crashed by 95.08% to $338000.0 in 2025.
  • Per Business Quant, the three most recent readings for PMCB's Other Non-Current Liabilities are $338000.0 (Q2 2025), $6.9 million (Q4 2024), and $980000.0 (Q3 2024).